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Available online 21 September 2018Objective: Sleep disturbance is a known risk factor for depression, but it is not known whether sleep disturbance
contributes to greater risk of depression in those infected with human immunodeficiency virus (HIV+) as com-
pared to those uninfected with HIV (HIV-).
Methods: Using data from the Multicenter AIDS Cohort Study, a population-based prospective study of men who
have sex with men (MSM), self-reported sleep disturbance (N2 weeks) and depressive symptoms (Clinical Epi-
demiologic Scale for Depression, CES-D) were assessed every 6 months over 12 years of follow-up. Adjusted
mixed effects logistic regression analyses tested whether sleep disturbance predicted depression (CES-D ≥ 16)
at the immediate subsequent visit, and so on over 12 years, in non-depressed HIV+(N= 1054; 9556 person-
visits) and non-depressed HIV- (N=1217; 12,680 person-visits). In HIV+ vs. HIV- MSM, linearly estimated av-
erage incidence of depression and normalized cumulative rate of depression over 12 years were compared.
Results: In the HIV+ MSM, sleep disturbance was associated with a significant increase in depression 6 months
later (OR = 1.6; 95% CI, 1.30, 1.96), which was significantly greater (P b .05) than in HIV- MSM (OR = 1.16;
95% CI, 0.94, 1.44). HIV status and sleep disturbance interacted (P b .001), such that incidence of depression
and normalized cumulative rate of depression were greater in HIV+with sleep disturbance than in HIV+with-
out sleep disturbance and HIV- groups (all P's b 0.001).
Conclusions:HIV+personswho report sleep disturbance represent a high risk group to bemonitored for depres-
sion, and possibly targeted for insomnia treatment to prevent depression.
Fund: National Institute of Allergy and Infectious Diseases.euroimmunology
ngeles, CA 90095,
. This is an open©2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Inflammation1. Introduction
An estimated 36·7 million people worldwide are infected with HIV,
and over 1·2 million persons in the US live with HIV [1]. However, for
many HIV-infected (HIV+) individuals, improved survival is complicat-
ed by the long-term behavioral consequences of HIV infection and its
treatment [2]. Indeed, major depression is more than three to four
times more prevalent in HIV+ persons than in persons who are not, UCLA Semel
United States.
access article underinfected with HIV (HIV-). Among persons with HIV, the estimated life-
time prevalence of depressive disorders is as high as 22% to 45% [2,3].
Furthermore, despite treatment with antiretroviral therapy (ART) [4],
and control of HIV replication and reductions in HIV viral load [5], per-
sons with HIV are at increased risk for depression. Understanding the
factors associated with depression in persons living with HIV is needed
to improvemethods to identify the risk for depression,which could lead
to targeted interventions for depression prevention.
Insomnia and self-reported sleep disturbance are known risk factors
for depression [6], and sleep complaints prospectively predict depres-
sion, independent of prior history of depression, other depressive symp-
toms, and use of antidepressant medications among communitythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in context
Evidence before this study
Recent systematic reviews have concluded that, among non-
depressed adults in the community, sleep disturbance predicts
subsequent depression. Empirical studies have found that major
depression is three to four times more prevalent in persons infect-
ed with human immunodeficiency virus (HIV+) than in non-
infected persons (HIV-); men who have sex with men (MSM) are
especially vulnerable. The symptoms of HIV infection (HIV viral
load, inflammation) and its treatment (highly active antiretroviral
therapy [HAART]) also increase the risk of sleep disturbance. To
date, however, no study has examined the prospective relation-
ship between sleep disturbance and depression among MSM, or
compared the magnitude of the relationship in HIV+ and HIV-
men.
Added value of this study
Using data from the Multicenter AIDS Cohort Study (MACS) with
over 2500 participants and N22,000 person-visit observations
over 12 years, this is the first prospective study to find that
sleep disturbance contributes to greater risk of depression in
HIV+ MSM as compared to HIV- MSM (P b 0·05). Moreover,
we found a significant interaction between sleep disturbance
and HIV status (P b 0·001), such that HIV+MSMwith sleep dis-
turbance had a rate of depression (31·8 cases per year per 100),
which was nearly twice that found in HIV- MSM without sleep
disturbance.
Implications of all the available evidence
Among HIV+, those with sleep disturbance require monitoring
because they are at high-risk of depression. More effective identi-
fication of those at risk for depression, along with improved man-
agement of depression in HIV+, could improve adherence to
HAART,mitigate adversemedical outcomes, and reducemortality
and suicide. Randomized controlled trials are needed to determine
if treating sleep disturbance will reduce depression – and its ad-
verse consequences – in people with HIV+.
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populations may not generalize to HIV+; HIV infection and treatment
introduce several extraneous variables (e.g. highly active antiretroviral
therapy (HAART) and HIV viral load). Indeed, HIV+ persons show in-
creased rates of insomnia [8,9] and depression [2,3], in which the
cross-sectional relationship between sleep disturbance and depression
is amplified [9]. Yet, no prospective study has examined whether sleep
disturbance contributes to greater risk of depression in HIV+ as com-
pared to HIV-.
Inflammation, a hallmark of HIV infection even in those whose viral
load is well suppressed [10,11], contributes to depression risk [12].
Moreover, sleep disturbance induces activation of inflammatory signal-
ing independent of other factors that can drive inflammation, such as
non-white ethnicity, smoking, and obesity [13]. It is not knownwhether
inflammation also contributes to depression and subsequent sleep dis-
turbance in HIV+ persons.
To address these questions, we examined men who have sex with
men (MSM), a population at heightened risk of depression [14], who
are also at substantial risk of HIV infection. MSM account for more
than half of all new HIV infections in the U.S. annually [15]. In this
study, we examined: [1] differences between HIV+ and HIV- MSM in
the prevalence of sleep disturbance and clinically relevant depressivesymptoms (defined by a score ≥ 16 on the Clinical Epidemiologic Scale
for Depression (CES-D [16], hereafter referred to as ‘depression’); [2]
the prospective association between sleep disturbance and depression
6 months later, repeatedly tested over 12 years follow-up, comparing
HIV+ and HIV- MSM; [3] among HIV+MSM, the associations between
sleep disturbance, inflammation as indexed by levels of C-reactive pro-
tein (CRP), and depression, taking into account use of HAART and HIV
viral load; and [4] the linearly estimated average incidence of depres-
sion, and normalized cumulative rate of depression cases over the
12 years, comparing HIV+ vs. HIV- MSM, stratified by presence or ab-
sence of sleep disturbance.
2. Methods
2.1. Participants
Data from the Multicenter AIDS Cohort Study (MACS), an
ongoing prospective study of HIV- and HIV+ MSM, were used. As de-
tailed previously [17], participants (N = 5622) were enrolled
from 1984 through 1991 from four sites in the USA: Baltimore,
Maryland; Chicago, Illinois; Los Angeles, California; Pittsburgh, Pennsyl-
vania. An additional 1350 men were enrolled between 2001 and
2003 [18]. The MACS was approved by the Institutional Review Board
(IRB) at the four study sites, and each participant provided informed
consent.
At semi-annual intervals, participants underwent standardized
questionnaires, physical examinations, and blood sampling. Beginning
with data collected at October 1, 2001 (i.e., visit 36), symptoms of
sleep disturbance were systematically evaluated; hence, we present
data from visit 36 to visit 60 (i.e., 25 separate visits over 12 years; Octo-
ber 2001 to October 2012). The number of MACS participants with
available data on both sleep disturbance and depressive symptoms var-
ied at each study visit. As an example, data were available in 973 HIV-
and 769 HIV+ MACS participants at visit 36 (September 30, 2001),
and in 1335 HIV- and 1244 HIV+ MACS participants at visit 41
(March 31, 2004), due to enrolment of additional participants between
2001 and 2003.
2.2. Measurement of sleep disturbance
At each visit, symptoms of sleep disturbance were evaluated with
two questions: 1) “are you currently experiencing ‘insomnia or prob-
lems sleeping?”; and 2) “have such sleep problems lasted for two
weeks or longer?” As previously reported [19], these two questions
show a high sensitivity in the identification of insomnia disorder as di-
agnosed by clinician-based interview and Diagnostic and Statistical
Manual criteria [20]. At each visit, we categorized participants as
sleep-disturbed if they answered yes to both questions; sleep distur-
bance was treated as a binary variable.
2.3. Measurement of depressive symptom and definition of depression
The 20-item CES-D assesses depressive symptom severity, in
which each item receives a score of 0–3, with CES-D total score ranging
from 0 to 60 [21]. In the MACS cohort, a threshold CES-D ≥ 16 provides
highest sensitivity in classifying depression, whereas CES-D ≥ 20 pro-
vides highest specificity [22]. In this study, the itemon sleep disturbance
(‘my sleepwas restless’) was removed from the CES-D, and ‘depression’
was categorized if participants scored CES-D ≥ 16 on the 19-item CES-D.
Hence, adjusting for 3 points for item removal, a CES-D N 16 threshold
retains optimal specificity, and is also mid-range between adjusted
CES-D thresholds of 19 and 13 (i.e, highest and lowest estimates of de-
pression caseness in HIV-infected men) [22–24]. General population
norms use a CES-D ≥ 16 threshold for categorization of depression
based on the 20-item CES-D [21,24].
Table 1
Demographic and clinical characteristics of the HIV-uninfected (HIV-) and HIV-infected
(HIV+) MACS participants at visit 41.
Variable HIV- (N = 1335) HIV+ (N = 1244) P a
Age, mean years (SD) 47.9 (11·5) 45·2 (9·0) b0·001
BMI, mean kg/m2 (SD) 26·8 (5·2) 25·2 (3·9) b0·001
Race, white, no· (%) 730 (75·0) 458 (68·2) b0·001
Smoker, never, no. (%) 264 (27.1) 194 (25·2) 0·002
Sleep disturbance, no. (%) 206 (21.2) 247 (32.1) b0.001
Depression (CES-D ≥ 16) no. (%) 199 (20·5) 200 (26·0) 0·006
Antidepressant use, no. (%) 178 (18·3) 190 (24·7) 0·001
HAART use, no. (%) 648 (84·3)
HIV viral load, no. (%)
b50 copies/ml 418 (54·4)
51–10,000 copies/ml 185 (24·1)
N10,000 copies/ml 166 (21·6)
CRP, mg/l, mean (SD)b 3·2 (6·9)
a Comparison by chi-square or t-test.
b for CRP data, N= 1061.
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Other factors associated with sleep disturbance and depressive
symptoms were assessed [13] and used as covariates in the analyses:
age, ethnicity (i.e., White/Black/Other), body mass index (BMI; kg/m
[2]), and smoking (i.e., ‘never’, ‘former’, or ‘current’). For HIV+ partici-
pants, additional covariates at each visit were current use of highly ac-
tive antiretroviral therapy (HAART), and HIV viral load (b50 copies/
ml, 51–10,000 copies/ml and N 10,000 copies/ml). Within a subsample
of HIV+ participants, data were available for serum levels of CRP and
assayed as previously described [11].
2.5. Statistical analysis
Stata version 12·0 was used for all statistical analyses. Participant
characteristics for HIV- and HIV+ groups were compared using chi-
square or t-tests. Study visit 41 (April–September 2004) was selected
for these comparisons, because it occurred after the expandedMACS en-
rollment in 2001–2003, and was the first visit to contain data on CRP
from all study centers.
The primary hypothesis was that sleep disturbance at a study visit
predicted lagged depression (as defined by CES-D ≥ 16) at the subse-
quent visit 6 months later. This hypothesis was tested using a mixed
effects logistic regression model, across a maximum of 24
exposures per subject (i.e., sleep disturbance at visits 36, 37, 38 and so
on to 59, predicting depression at the immediate subsequent visit, 37,
38, 39, and so on to 60). Specifically, sleep disturbance at visit 36
was used to predict depression outcome at visit 37, and so on
repeatedly across 24 separate exposures over 12 years duration. If the
predictor visit was missing, the next earliest available visit was used.
Observations were excluded for two reasons. If the subject was de-
pressed (i.e., CES-D ≥ 16) at the predictor visit they were excluded to
eliminate the confounding influence of current depression at the predic-
tor visit. Additionally, participants who reported use of antidepressant
medications at the predictor visit (self-reported use in the last
6 months) were also excluded because antidepressant medication use
may indicate the presence of a current depressive episode, and antide-
pressant medication use is often associated with sleep disturbance,
which may confound the link between sleep disturbance and depres-
sion. Our procedures yielded the following total number of unique par-
ticipants across the duration of the study: HIV- (N = 1217; 12,680
person-visits) and HIV+ (N= 1054; 9556 person-visits). Participants
were treated as a random factor and the covariance matrix for the re-
peated measures was unstructured.
All analyses were conducted separately by HIV status to allow for
step comparisons between HIV status, recognizing also that disease
specific predictors were only available in the HIV+ group. Analytic
models were adjusted for age (step 1); and ethnicity; BMI; and smoking
(step 2); in the HIV+ group only, for use of HAART medication and HIV
RNA (step 3). Additionally, to examine whether associations were af-
fected by HIV duration, analyses adjusted for time between known or
estimated date of HIV infection and study visit; this covariate did not
alter any of the associations and is not shown.
To evaluate whether the association between sleep disturbance and
depression differed between the HIV- and HIV+ groups, we combined
the two groups, and adjusted for steps 1 and 2 as described above. In
the first model, a main effect for HIV status was entered, and in the sec-
ond model, an interaction term between HIV status and sleep distur-
bance status was also included. The significance of the interaction
between the two models was tested using a likelihood ratio test.
As noted, evidence of a depression (CES-D ≥ 16) or use of antidepres-
sant medication at the predictor visit resulted in exclusion. However,
because sleep disturbancemight be only one component of a prodromal
depression that has not yet met criteria for depression, sensitivity anal-
ysis was conducted to adjust for any depressive symptoms (i.e., CES-D)
at each predictor visit.It is also possible that the associations between sleep disturbance
and depression might be confounded with physical health symptoms
from HIV infection or related co-morbidities, even though the CES-D is
a validated depression scale in HIV infected person [22,23,25]. To rule
out the confounding influence of somatic symptoms, we conducted fur-
ther sensitivity analyses that used the CES-D ‘depressed affect’ subscale
(i.e., CES-D 15 item), which excludes 5 somatic items associated with
symptoms of HIV infection and co-morbidities (i.e., fatigue, insomnia,
apathy, difficulty in concentrating, and poor appetite). Participants
were categorized as depressed if they scored ≥11 on the 15-item CES-
D, as previously reported [26].
In the HIV+ group for whom serum CRP levels were available, sec-
ondary analyses evaluated whether inflammation contributed to de-
pression in HIV+ persons by entering natural log-transformed CRP
values into the model and examining whether CRP had a main effect,
and whether inclusion of CRP values altered the relationship between
sleep disturbance and depression. Additional sensitivity analyses ex-
cluded those with CRP levels N10 mg/L to eliminate participants with
possible acute infection; as CRP was over-sampled in those who tested
positive to Hepatitis C virus (HCV) (3·1%), models were also tested ex-
cluding those with current positive HCV RNA.
As noted, presence of depression (CES-D ≥ 16) at the predictor visit
resulted in exclusion; hence subsequent depression 6 months later
was an incident episode of depression. Using observed data, analyses
compared the incidence rate of episodes of depression between the
four groups (HIV- with and without sleep disturbance, and HIV+ with
and without sleep disturbance) with a Wald chi-square test to deter-
mine main effects for HIV status, sleep disturbance, and the interaction
between HIV status and sleep disturbance. To estimate the rate of accu-
mulation of incident episodes of depression in the four groups, depres-
sion observed for each visit was calculated and applied as if groups of
100 people eachwere thus exposed to generate a linearly estimated av-
erage incidence of depression episodes per 100 participants. Total cu-
mulative numbers of “new” episodes of depressions for each of the
groups over the 12 year period were plotted against time, fit to linear
and non-linear functions, and compared, adjusting for the covariates.3. Results
3.1. Sample characteristics
Compared to HIV- participants (N=1335), HIV+ participants (N=
1244),were younger,more likely to be non-white, had lower bodymass
index, and were more likely to have ever smoked (Table 1, all P's ≤
0·002). In addition, compared to HIV-, the HIV+ participants had
higher rates of sleep disturbance, depression as defined by clinically
Table 2
Prospective associations between sleep disturbance and depression 6 months later, stratified by HIV status, repeated over 12 years duration, Data are displayed as odds ratio (95% confi-
dence intervals).
HIV- (N = 1217) HIV+ (N = 1054)
12,680 person-visits 9556 person-visits
Model 1a Model 2b Model 1a Model 2b Model 3c
Sleep disturbance No Ref Ref Ref Ref Ref
Yes 1·16 (0·94–1·44) 1·17 (0·95–1·45) 1·60 (1·30–1·96)⁎⁎ 1·63 (1·33–2·00)⁎⁎ 1·52 (1·29–1·80)⁎⁎
Age (years) 0·97 (0·96–0·98)⁎⁎ 0·98 (0·97–0·99)⁎ 0·97 (0·96–0·98)⁎⁎ 0·98 (0·96–0·99)⁎⁎ 0·98 (0·96–0·99)⁎
Race White Ref ref ref
Black 2·25 (1·54–3·27)⁎⁎ 1·66 (1·20–2·29)⁎ 1·62 (1·17–2·24)⁎
Other 1·95 (0·97–3·92) 1·46 (0·83–2·57) 1·48 (0·84–2·61)
BMI (kg/m2) 1·00 (0·98–1·03) 1·02 (0·99–1·05) 1·02 (0·99–1·05)
Smoker Never Ref ref ref
Former 1·42 (1·01–1·99)⁎ 1·17 (0·82–1·67) 1·17 (0·82–1·66)
Current 2·19 (1·49–3·22)⁎⁎ 1·64 (1·13–2·36)⁎ 1·61 (1·12–2·33)⁎
HAART No ref
Yes 1·15 (0·80–1·65)
Viral load (copies/ml) b 50 ref
51–10,000 1·10 (0·87–1·40)
N10,000 1·38 (1·04–1·85)⁎
⁎ p b 0·05.
⁎⁎ p b 0·001.
a Model 1: Adjusted for age.
b Model 2: Model 1 + race, BMI, smoking.
c Model 3: Model 2 + HAART, and viral load.
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antidepressantmedications (all P's ≤ 0·006). AmongHIV+participants,
the large majority used HAART (84·3%), and about one fifth had an HIV
viral load N10,000 copies/ml; mean serum CRP was 3·2 mg/l (SD, 6·9;
median = 1.4 mg/l, interquartile range = 2.7 mg/l).
3.2. Associations between sleep disturbance and depression by HIV status
In the HIV- participants, sleep disturbance was not associated with
depression six months later (odds ratio, OR = 1.16; 95% CI, 0.94, 1.44)
(Table 2). In contrast, in the HIV+ participants, sleep disturbance was
associated with a significant increase in the likelihood of a subsequent
depression (OR = 1.6; 95% CI, 1.30, 1.96). These odds were unaffected
by adjustment for covariates (model 2), or in the HIV+ participants,
by HAART use or viral load (model 3). Within the HIV+ participants,Table 3
Prospective associations between sleep disturbance and depression. 6 months later, in HIV+pa
(95% confidence intervals).⁎
HIV+ with CRP
3691 person-vi
Model 1a
Sleep disturbance No ref
Yes 1·98 (1·4–2·80
Age (years) 0·96 (0·93–0·9
Race White
Black
Other
BMI (kg/m2)
Smoker Never
Current
HAART No
Yes
Viral load (copies p/ml) b 50
51–10,000
N10,000
Ln CRP (mg/l)
⁎ p b 0·05.
⁎⁎ p b 0·001.
a Model 1: Adjusted for age.
b Model 2: Model 1 + race, BMI, and smoking.
c Model 3b: Model 2 + HAART, viral load, and C-reactive protein.high viral load (N10,000 copies/ml), but not use of HAART,was a predic-
tor of depression, but sleep disturbance andhigh viral load did not inter-
act to further increase the risk of depression (data not shown, available
from authors). In both HIV- and HIV+ participants, older age was asso-
ciated with significantly lower risk of depression, whereas Black ethnic-
ity and smoking predicted increased risk of depression (Table 2).
Additional analyses explored whether sleep disturbance predicted de-
pression if the duration of exposure was extended from six months to
one year. In theHIV- participants, sleep disturbancewas now associated
with depression six months later (odds ratio, OR = 1.29; 95% CI, 1.12,
1.44) adjusting for model 2 covariates. In the HIV+ participants, sleep
disturbance remained associated with depression (OR = 1.7; 95% CI,
1.40, 2.2) adjusting for model 3 covariates.
Given that the CES-D threshold ≥16was adjusted for scoringwithout
the sleep item, exploratory analyses examined CES-D thresholds fromrticipants with CRP data, repeated over 12 years duration, Data are displayed as odds ratio
data (N= 872)
sits
Model 2b Model 3bc
ref ref
)⁎⁎ 2·00 (1·42–2·84)⁎⁎ 2·03 (1·44–2·88)⁎⁎
8)⁎⁎ 0·96 (0·94–0·98)⁎⁎ 0·97 (0·94–0·99)⁎⁎
ref ref
1·39 (0·88–2·21) 1·32 (0·83–2·09)
1·01 (0·95–1·05) 1·04 (0·46–2·32)
1·00 (0·95–0·05) 0·99 (0·95–1·05)
ref ref
1·01 (0·61–1·68) 1·00 (0·60–1·66)
1·35 (0·79–2·28) 1·30 (0·76–2·20)
ref
1·19 (0·67–2·10)
ref
1·37 (0·91–2·06)
1·73 (1·08–2·77)⁎⁎
1·03 (0·90–1·19)
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caseness, as well as varying metrics of sensitivity and specificity
[22–24]. Across this range of CES-D threshold scores, results were
similar with significant OR's ranging from 1.63 to 2.10 for the HIV+
(all P's b 0.05) and OR's ranging from 1.10 to 1.24 in the HIV- in which
the CES-D threshold ≥19 was significant (P b .05).
In the combined sample of HIV- and HIV+ participants, we tested
the interaction between HIV status and sleep disturbance. Likelihood
ratio tests demonstrated that the association between sleep disturbance
and depression was significantly greater (P b .05) in the HIV+ as com-
pared to the HIV- participants, and these results were similar when the
duration of exposure was extended to one year (P= .06).
Given that sleep disturbance might be a prodromal symptom of de-
pression that does not meet criteria for depression (i.e., CES-D ≥ 16),
sensitivity analyses were conducted to test whether sleep disturbance
predicted depression, independent of all other depressive symptoms.
When CES-D scores at each predictor visit were included in the model,
sleep disturbance remained associated with depression in the HIV+
(1·21, 95% CI 1·0–1·42), but not in the HIV- participants (1·02, 95%
CI 0·83–1·24). As would be expected, low levels of other depressive
symptoms (i.e., below the CES-D ≥ 16 threshold) were associated with
depression 6 months later in the HIV- (OR = 1·23, 95% CI 1·21–1·25)
and in the HIV+ participants (1·22, 95% CI 1·20–1·25).
Because living with HIV is associated with somatic symptoms, we
conducted sensitivity analyses that excluded somatic items from the
CES-D. The association between sleep disturbance and depression, ex-
cluding such somatic symptoms and adjusting for covariates, was
strengthened in both the HIV- (OR = 1·36, 95% CI 1·09–1·68) and
HIV+ participants (OR = 1·79, 95% CI 1·47–2·18).
3.3. Associations between inflammation and depression
In the subsample of HIV+ participants for whom CRP values were
available, levels of CRP did not predict depression (Table 3). Additional-
ly, including CRP in the model did not alter the association between
sleep disturbance and depression in HIV+ participants (Table 3). Fur-
thermore, there was no interaction between sleep disturbance and
CRP levels (b3mg/l and ≥ 3mg/l; P=0·8).When those with CRP levelsFig. 1. Normalized cumulative number of CES-D defined depression (i.e., CES-D ≥ 16) as estima
HIV+without sleep disturbance; HIV- with sleep disturbance; and HIV- without sleep disturba
ticipants: HIV+with sleep disturbance, 31·8 per year (95% CI: 31·6–32·0); HIV+without sle
turbance, 23·1 (95% CI: 22·8–23·3); and HIV-without sleep disturbance, 15.4 (95% 15·3–15·5
other (all P's b 0·01).≥10mg/l were excluded, the association between sleep disturbance and
depression remained (adjusted OR= 1·77, 95% CI 1·33, 2·34). Finally,
given the high prevalence of Hepatitis C infection in those with HIV,
analyses were repeated excluding those who tested positive for Hepati-
tis C; the association between sleep disturbance and depression also
remained (adjusted OR = 2·16, 95% CI 1·49–3·13).
3.4. Sleep disturbance and depression incidence by HIV status
Data at each visit was used to calculate the incidence of episodes of
depression in four groups: HIV- participantswith andwithout sleep dis-
turbance, and HIV+ participants with and without sleep disturbance. A
simple linear function fit the data extremely well (all R [2] N 0.98) and
indicated little change in incidence of episodes of depression from one
visit to the next over the entire 12 years for all four groups. The linearly
estimated average incidence of depression per 100 participants was
15·4 cases per year (95% CI 15·3–15·5) in the HIV- without sleep dis-
turbance; 23·1 cases per year (95% CI 22·8–23·3) in the HIV- with
sleep disturbance; 18·2 cases per year (95% CI 18·1–18·4) in the
HIV+ without sleep disturbance, 31·8 cases per year (95% CI
31·6–32·0) in the HIV+ with sleep disturbance. Wald chi-square test
showed a main effect for HIV status (P b 0·001), for sleep disturbance
(P b 0·001), and the interaction between HIV status and sleep distur-
bance (P b 0·001); adjusting for age, BMI, race, and smoking status
did not alter the interaction between HIV status and sleep disturbance
(P= 0·002). Fig. 1 presents the plots of the cumulative number of de-
pressions in the four groups; each of these rate estimates were signifi-
cantly different from each other (all P's b 0·01).
4. Discussion
Usingdata from N2500menwhohave sexwithmen (MSM) enrolled
in a longitudinal cohort study, this prospective investigation is the first
to report that sleep disturbance contributes to greater risk of depression
in HIV+ as compared to HIV- MSM. Additionally, this study found that
those infected with HIV have greater prevalence of self-reported sleep
disturbance, greater prevalence of clinically relevant symptoms indica-
tive of depression, and are more likely to use antidepressantted in 100 participants per group in four exposure groups: HIV+ with sleep disturbance;
nce. The rate of slope is the linearly estimated annual incidence of depression per 100 par-
ep disturbance, 18.2 without sleep disturbance (95% CI: 18·1–18·4); HIV- with sleep dis-
). Each of these predicted average incidence estimates are significantly different from each
459M.R. Irwin et al. / EBioMedicine 36 (2018) 454–460medications. Furthermore, with 25 repeated visits of data collection and
over 22,000 person-visit observations over 12 years, we provide evi-
dence for thefirst time that sleep disturbance andHIV status significant-
ly interact to predict depression in which the risk for depression was
significantly greater in those with sleep disturbance who were HIV+
as compared to those who were HIV-. Importantly, sleep disturbance
predicted depression independent of demographic and clinical charac-
teristics, as well as use of antiretroviral therapy and HIV viral load, con-
sistent with cross-sectional evidence [9].
Among those who were HIV+ with sleep disturbance, the aver-
age estimated incidence of depression over 12 years was significantly
higher than that among the other three groups: HIV+ without sleep
disturbance, HIV- with sleep disturbance, and HIV- without sleep
disturbance. Indeed, nearly 1 in 3 HIV+ with sleep disturbance had
incident episodes of depression per year, which was an annual rate
of depression incidence that more than twice that found in HIV-
without sleep disturbance, and greater than the rates found in com-
munity dwelling adults with insomnia [6]. Our findings suggest
that sleep disturbance places HIV+ persons at markedly increased
risk of clinically significant depressive symptoms, above the risk as-
sociated with HIV status or sleep disturbance alone.
Inflammation is reported to predict depression in adult commu-
nity samples [12,27]. In HIV+, who had, on average, high levels of
CRP (i.e., N3 mg/l), this measure of systemic inflammation was not
associated with depression 6 months later. Moreover, levels of CRP
did not attenuate the prospective association between sleep distur-
bance and depression. Nevertheless, evidence of active HIV replica-
tion (i.e., viral load N10,000 p/ml) was a significant predictor of
depression, which indicates that MSM who show both sleep distur-
bance and high levels of HIV viral load may be especially vulnerable
to depression. However, sleep disturbance and high viral load did
not interact to increase the risk of depression, possibly because few
number of participants had high viral loads. Prior findings demon-
strate that antiretroviral therapy is associated with lower risk for de-
pression, which might be a due to the ability of antiviral therapy to
reduce viral load [28].
Given the prevalence of complaints of sleep disturbance [8,9] and
depression [2,3] in HIV-infected populations, and evidence that HIV
infection magnifies the prospective risk for depression in those
with sleep disturbance, HIV+ MSM represent a high risk group for
depression monitoring. Additionally, this group might be targeted
for the treatment of sleep disturbance for the prevention of depres-
sion. Efforts to decrease the prevalence of depression in HIV+, in
turn, might improve adherence to HAART [29–31] and mitigate ad-
verse medical outcomes [25] and mortality risk [32–36].Moreover,
treatments that target insomnia complaints are thought to optimize
the efficacy of depression prevention efforts, by reducing the number
needed to treat to achieve benefit. Indeed, cognitive behavioral ther-
apy for insomnia (CBT\\I), as well as mindfulness based interven-
tions (MBI), achieve N50% clinical response rate [37–39], suggesting
that such prevention strategies are feasible in collaborative care
(i.e., CBT\\I) or community settings (i.e., MBI), with the potential
to prevent incident depression in HIV+MSM. No study to our knowl-
edge has examined the efficacy of CBT-I for the treatment of insom-
nia in HIV+ and/or MSM populations.
Several limitations require consideration. First, sleep disturbance
was assessed by two questions, and it is possible that participants
were classified as having sleep disturbance even though symptom
severity may indicate subsyndromal insomnia. Diagnostic insomnia,
as opposed to subsyndromal insomnia (i.e., insomnia complaints), is
a more robust predictor of depression [7]. Additionally, objective as-
sessment of sleep disturbance by actigraphy, for example, would add
value to further work. Second, identification of cases of incident
depression relied on a cutpoint ≥16 on the CES-D, or a threshold se-
verity of depressive symptoms. Although this threshold of symptom
severity is often used to indicate depression and correlates withdiagnostic depression [24], diagnosis of depression with structured
clinical interviews and diagnostic criteria are the gold standard.
Importantly, CES-D threshold across a range of scores used to identi-
fy depression caseness in HIV+ yielded results identical to the CES-D
≥ 16 threshold. Third, this study examined a short exposure window
(i.e., 6 months) of sleep disturbance on depression. Indeed when the
exposure window wasextended to a year or longer, the association
between sleep disturbance and depression became significant in
HIV- consistent with meta-analytic findings [6]; the association be-
tween sleep disturbance and depression remained significantly
more robust in HIV+ as compared to HIV- at both 6 months and
one years exposure. Finally, the sample focused on MSM, who as a
group are at high risk for sleep disturbance, depression, and HIV.
Thus, findings may not generalize to women or a more ethnically di-
verse sample of HIV+ persons.
Despite these limitations, our findings demonstrate that HIV+
with sleep disturbance show significantly greater risk of depression
as compared to HIV-. Over 12-year follow-up, HIV+ with sleep dis-
turbance show a normalized rate of accumulation of depression
that is over twice as great as HIV- without sleep disturbance. Future
research should target the treatment of sleep disturbance in HIV+
and evaluate whether such insomnia treatment reduces the risk of
depression.
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